



Taylor, G. M. J., & Munafò, M. R. (2018). What about treatment of smoking to improve survival and reduce depression? *Lancet Psychiatry*, 5(6), 464. [https://doi.org/10.1016/S2215-0366\(18\)30132-9](https://doi.org/10.1016/S2215-0366(18)30132-9)

Peer reviewed version

License (if available):
CC BY-NC-ND

Link to published version (if available):
[10.1016/S2215-0366\(18\)30132-9](https://doi.org/10.1016/S2215-0366(18)30132-9)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Lancet Publishing Group at <https://www.sciencedirect.com/science/article/pii/S2215036618301329> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Title: What about treating smoking to improve survival and depression? Reply to Mulick et al (2018)

Authors: Gemma MJ Taylor¹, Marcus R Munafò¹

Affiliation: MRC Integrative Epidemiology Unit, UK Centre for Tobacco and Alcohol Studies, School of Experimental Psychology, University of Bristol, United Kingdom

Correspondence to: Dr Gemma Taylor, gemma.taylor@bristol.ac.uk, MRC Integrative Epidemiology Unit, UK Centre for Tobacco and Alcohol Studies, School of Experimental Psychology, University of Bristol, 12a Priory Road, Bristol, BS8 1TU, United Kingdom

Comment:

Mulick and colleagues report long-term follow-up data from two randomised controlled trials (RCTs) of depression treatment for people with comorbid depression and cancer¹. The main trials, SMaRT Oncology-2 for people with good prognosis cancers, and SMaRT Oncology-3 for patients with poor prognosis cancers, aimed to determine whether “Depression Care for People with Cancer” (DCPC) reduced depression symptoms. In their analysis of the follow-up data, the researchers aimed to identify whether DCPC also improved survival rates. Across the two RCTs 642 patients were recruited and randomised to receive DCPC, or treatment as usual.

Much of the association between depression and cancer can be explained by high smoking prevalence among people with depression². We know that people with depression are about twice as likely to smoke, and are more heavily addicted compared with the general population³. These inequalities contribute to a reduction in life-expectancy of almost 14 years for people with depression compared to those without depression², even though they are motivated to stop smoking³. Given this, we were surprised that: 1) participants’ smoking status was not reported, and 2) the comorbid association between mental illness and smoking was not discussed. Smoking is the leading cause of cancer, and stopping smoking after diagnosis of cancer can improve prognostic outcomes⁴. Moreover, stopping smoking is also associated with improvements in mental health, even in people with psychiatric conditions⁵. There is therefore a strong case for offering parallel treatment of smoking and depression; by not offering smokers with depression help to quit we may be worsening both their mental and physical health.

We are currently investigating the implementation of smoking cessation treatment alongside routine psychological care for smokers with depression and/or anxiety. The preliminary qualitative work that we have conducted suggests that psychological therapists have the proficiency to deliver such an intervention and feel that part of their role is to help willing clients to make healthy lifestyle changes. In addition, we have identified the potential for a similar intervention to be tested in other primary or secondary care settings for smokers with comorbid mental-illness and smoking-related conditions, such as cancer or COPD. Due to the enormous beneficial impact that stopping smoking has on health outcomes, smoking cessation interventions are some of the most cost-effective treatments available to health services. Our research provides preliminary evidence that there are missed-opportunities to deliver such treatments in NHS services, and potentially in similar health care settings worldwide.

Reference:

1. Mulick, A, Walker, J, Puntis, S, Burke, K, Symeonides, S, Gourley, C, Wanat, M, Frost, C, Sharpe, M. Does depression treatment improve the survival of depressed patients with cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials. *The Lancet Psychiatry* **Available**, (2018).
2. Chang, C. K. *et al.* Life expectancy at birth for people with serious mental illness from a secondary mental health care case register in London, UK. *Am. J. Epidemiol.* **173**, S311 (2011).
3. Royal College of Physicians; Royal College of Psychiatrists. *Smoking and Mental Health*. (2013).
4. Parsons, A., Daley, A., Begh, R. & Aveyard, P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. *BMJ* **340**, (2010).
5. Taylor, G. *et al.* Change in mental health after smoking cessation: systematic review and meta-analysis. *BMJ* **348**, (2014).